A Phase 3 interventional study of TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 159 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one has the largest enrollment, is one of 5 that started in 2015, is one of 25 in phase 3, and was the 9th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 25 · Phase 4 3
First in 2012; this study’s year is marked. 5 started in 2015.
This study's enrollment of 1,131 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 100 across the 43 interventional studies. Of the 36 that completed or were terminated, 31 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 5 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 2nd largest by enrollment of the 116 interventional ones that give a count, is one of 12 that started in 2015, is one of 62 in phase 3, and was the 46th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing tezacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies testing tezacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, open-label, 3-part rollover study in subjects with CF who are homozygous or heterozygous for the F508del-CFTR mutation and who participated in studies VX13-661-103 (Study 103, NCT02070744), VX14-661-106 (Study 106, NCT02347657), VX14-661-107 (Study 107, NCT02516410), VX14-661-108 (Study 108, NCT02392234), VX14-661-109 (Study 109, NCT02412111), VX14-661-111 (Study 111, NCT02508207), VX15-661-112 (NCT02730208), and VX16-661-114 (NCT03150719). The study is designed to evaluate the safety and efficacy of long-term treatment of VX-661 in combination with ivacaftor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A:
Participants re-enrolling in the Part A Treatment Cohort must meet all of the following criteria:
Participants entering the Part A Observational Cohort must meet the following criteria:
Part B:
Participants who meet all of the following inclusion criteria will be eligible for Part B.
Participants re enrolling in Part B must meet all of the following criteria:
Part C:
Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Participants who received either TEZ/IVA, IVA monotherapy or Placebo in parent studies 103,106,107,108,109 and 111 were administered TEZ 100 milligram (mg)/IVA 150 mg fixed-dose tablet in the morning and IVA 150 mg mono tablet in the evening for 96 weeks. Part B: Participants who received either TEZ/IVA, IVA monotherapy or Placebo in parent studies 106,108,109,112 and 114 were administered TEZ 100 mg/IVA 150 mg fixed-dose tablet in the morning and IVA 150 mg mono tablet in the evening for 96 weeks. Part C: Participants who received TEZ/IVA, IVA monotherapy or Placebo in parent studies 106,108, and 114 were administered TEZ 100 mg/IVA 150 mg fixed dose tablet in the morning and IVA 150 mg mono tablet in the evening for 192 weeks.
Drug: TEZ/IVA · Drug: IVA
Drug pages: Tezacaftor · Ivacaftor
Fixed dose tablet for oral administration.
Also known as: VX-661/VX-770, tezacaftor/ivacaftor
Tablet for oral administration.
Also known as: VX-770, ivacaftor
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 100
Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs
Time frame: Day 1 up to Week 100
Part C: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 196
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 106/110 Efficacy Set
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 108/110 Efficacy Set
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 111/110 Efficacy Set
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 106/110 Efficacy Set
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 108/110 Efficacy Set
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 111/110 Efficacy Set
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Number of Pulmonary Exacerbation (PEx) Events for 106/110 PEx Analysis Set
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
Time frame: From Baseline up to Study 110 Week 96
Part A: Number of Pulmonary Exacerbation (PEx) Events for 108/110 PEx Analysis Set
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline up to Week 96
Part A: Absolute Change in Body Mass Index (BMI) for 106/110 Efficacy Set
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Body Mass Index (BMI) for 108/110 Efficacy Set
BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Body Mass Index (BMI) for 103/110 Efficacy Set
BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Body Mass Index (BMI) for Study 111/110 Efficacy Set
BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in BMI Z-score for 106/110 Efficacy Set
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in BMI Z-score for 108/110 Efficacy Set
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 106/110 Efficacy Set
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 108/110 Efficacy Set
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/110 Efficacy Set
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Body Weight for Study 106/110 Efficacy Set
Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Body Weight for 108/110 Efficacy Set
Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Body Weight for 103/110 Efficacy Set
Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Body Weight for 111/110 Efficacy Set
Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Body Weight Z-score for 106/110 Efficacy Set
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Body Weight Z-score for 108/110 Efficacy Set
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Height Z-score for 106/110 Efficacy Set
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Absolute Change in Height Z-score for 108/110 Efficacy Set
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
Time frame: From Baseline at Study 110 Week 96
Part A: Time-to-first Pulmonary Exacerbation (PEx) for 106/110 PEx Analysis Set
Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan.
Time frame: 96 weeks
Part A: Time-to-first Pulmonary Exacerbation (PEx) for 108/110 PEx Analysis Set
Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan.
Time frame: 96 weeks
Part A: Plasma Concentrations of TEZ, TEZ Metabolite (M1-TEZ), Ivacaftor (IVA) and Ivacaftor Metabolite (M1-IVA)
Time frame: Week 24
Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: From Baseline at Study 110 Week 96
Part B: Absolute Change in Body Mass Index (BMI)
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).
Time frame: From Baseline at Week 96
Part B: Absolute Change in BMI Z-score
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Time frame: From Baseline at Week 96
Part B: Number of Pulmonary Exacerbation (PEx) Events
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
Time frame: From Baseline up to Week 96
This study consisted of 3 parts: Parts A, B, and C.
| Milestone | TEZ/IVA |
|---|---|
| Started | 1044 |
| Safety set | 1042 |
| Completed | 951 |
| Not completed | 93 |
| Withdrew: Adverse event | 17 |
| Withdrew: Withdrawal of consent (not due to ae) | 25 |
| Withdrew: Lost to follow-up | 12 |
| Withdrew: Death (not treatment emergent) | 1 |
| Withdrew: Other noncompliance | 6 |
| Withdrew: Physician decision | 6 |
| Withdrew: Parent study termination by sponsor | 1 |
| Withdrew: Commercial drug available | 5 |
| Withdrew: Other | 18 |
| Withdrew: Enrolled, but did not receive study drug | 2 |
| Milestone | TEZ/IVA |
|---|---|
| Started | 464 |
| Safety set | 463 |
| Completed | 228 |
| Not completed | 236 |
| Withdrew: Physician decision | 1 |
| Withdrew: Other | 1 |
| Withdrew: Enrolled, but did not receive study drug | 1 |
| Withdrew: Adverse event | 4 |
| Withdrew: Sponsor decision | 2 |
| Withdrew: Rolled over into another study | 25 |
| Withdrew: Withdrawal of consent (not due to ae) | 6 |
| Withdrew: Commercial drug is available for participant | 196 |
| Milestone | TEZ/IVA |
|---|---|
| Started | 204 |
| Safety set | 204 |
| Completed | 7 |
| Not completed | 197 |
| Withdrew: Physician decision | 5 |
| Withdrew: Adverse event | 1 |
| Withdrew: Other non-compliance | 2 |
| Withdrew: Rolled over into another study | 11 |
| Withdrew: Withdrawal of consent (not due to ae) | 4 |
| Withdrew: Commercial drug is available for participant | 174 |
| Participants | Part A: TEZ/IVA |
|---|---|
| Participants with TEAEs | 995 |
| Participants with SAEs | 351 |
| Participants | Part B: TEZ/IVA |
|---|---|
| Participants with TEAEs | 427 |
| Participants with SAEs | 136 |
| Participants | Part C: TEZ/IVA |
|---|---|
| Participants with TEAEs | 168 |
| Participants with SAEs | 44 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
| percentage points | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 2.1 (0.8 to 3.3) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 2.0 (0.7 to 3.2) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| percentage points | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 4.1 (2.2 to 6.0) |
| IVA-TEZ/IVA: Change at Week 96 | 6.7 (4.7 to 8.7) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 7.5 (5.6 to 9.4) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.
| percentage points | Part A: TEZ/IVA |
|---|---|
| Part A: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set | 2.7 ± 10.0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| percentage points | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 4.1 ± 10.2 |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 2.6 ± 6.6 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
| percent change | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 4.3 (2.1 to 6.5) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 4.2 (2.0 to 6.4) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| percent change | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 7.9 (4.7 to 11.1) |
| IVA-TEZ/IVA: Change at Week 96 | 11.6 (8.2 to 15.0) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 13.0 (9.7 to 16.2) |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.
| percent change | Part A: TEZ/IVA |
|---|---|
| Part A: Relative Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for 103/110 Efficacy Set | 6.4 ± 21.1 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| percent change | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 6.1 ± 14.4 |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 5.2 ± 11.5 |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
| PEx events | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA | 306 |
| TEZ/IVA-TEZ/IVA | 423 |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| PEx events | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA | 89 |
| IVA-TEZ/IVA | 51 |
| TEZ/IVA-TEZ/IVA | 46 |
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
| kg/m^2 | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 0.47 (0.30 to 0.65) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 0.38 (0.20 to 0.55) |
BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| kg/m^2 | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 1.07 (0.59 to 1.55) |
| IVA-TEZ/IVA: Change at Week 96 | 0.96 (0.45 to 1.47) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 1.05 (0.56 to 1.55) |
BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.
| kg/m^2 | Part A: TEZ/IVA |
|---|---|
| Part A: Absolute Change in Body Mass Index (BMI) for 103/110 Efficacy Set | 1.38 ± 1.73 |
BMI was defined as weight in kg divided by height in square meter (m\^2). Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| kg/m^2 | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 1.59 ± 2.08 |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 0.26 ± 0.88 |
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
| z-score | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 0.10 (-0.04 to 0.25) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | -0.14 (-0.28 to 0.00) |
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| z-score | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 0.11 (-0.32 to 0.54) |
| IVA-TEZ/IVA: Change at Week 96 | 0.07 (-0.52 to 0.65) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 0.30 (-0.21 to 0.80) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
| units on a scale | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 1.7 (-0.6 to 4.0) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 3.0 (0.7 to 5.3) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| units on a scale | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 10.3 (7.0 to 13.6) |
| IVA-TEZ/IVA: Change at Week 96 | 11.2 (7.7 to 14.7) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 13.8 (10.3 to 17.2) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.
| units on a scale | Part A: TEZ/IVA |
|---|---|
| Part A: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score for 103/110 Efficacy Set | 8.6 ± 12.1 |
Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
| kg | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 2.0 (1.4 to 2.5) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 2.1 (1.5 to 2.6) |
Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| kg | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 3.5 (1.9 to 5.1) |
| IVA-TEZ/IVA: Change at Week 96 | 3.5 (1.8 to 5.2) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 3.6 (2.0 to 5.2) |
Data are reported for TEZ/IVA-TEZ/IVA group (participants who received TEZ/IVA in both parent study 103 and in current study 110). Baseline was defined as the parent study baseline.
| kg | Part A: TEZ/IVA |
|---|---|
| Part A: Absolute Change in Body Weight for 103/110 Efficacy Set | 4.0 ± 5.0 |
Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 111 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 111 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| kg | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 4.2 ± 5.7 |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 0.6 ± 2.6 |
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
| z-score | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 0.07 (-0.06 to 0.20) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | -0.06 (-0.19 to 0.07) |
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| z-score | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 0.15 (-0.25 to 0.55) |
| IVA-TEZ/IVA: Change at Week 96 | 0.09 (-0.45 to 0.62) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 0.43 (-0.04 to 0.90) |
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline except for Placebo-TEZ/IVA category, for which baseline was study 110 baseline.
| z-score | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | 0.01 (-0.08 to 0.11) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 0.13 (0.04 to 0.22) |
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan. Baseline was defined as the parent study baseline.
| z-score | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA: Change at Week 96 | -0.04 (-0.23 to 0.15) |
| IVA-TEZ/IVA: Change at Week 96 | 0.20 (-0.05 to 0.45) |
| TEZ/IVA-TEZ/IVA: Change at Week 96 | 0.23 (0.00 to 0.46) |
Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 106 and TEZ/IVA in current study 110) and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 106 and in current study 110) as per pre-specified analysis plan.
| event-free probability | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA | 0.470 (0.402 to 0.535) |
| TEZ/IVA-TEZ/IVA | 0.438 (0.374 to 0.501) |
Time-to-first pulmonary exacerbation was analyzed using Kaplan-Meier estimates and expressed in terms of event-free probability. PEx was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. Data are reported separately for Placebo-TEZ/IVA category (participants who received placebo in parent study 108 and TEZ/IVA in current study 110); IVA-TEZ/IVA category (participants who received IVA monotherapy in parent study 108 and TEZ/IVA in current study 110); and TEZ/IVA-TEZ/IVA category (participants who received TEZ/IVA in both parent study 108 and in current study 110) as per pre-specified analysis plan.
| event-free probability | Part A: TEZ/IVA |
|---|---|
| Placebo-TEZ/IVA | 0.497 (0.383 to 0.601) |
| IVA-TEZ/IVA | 0.493 (0.372 to 0.603) |
| TEZ/IVA-TEZ/IVA | 0.639 (0.519 to 0.737) |
| nanogram/milliliter (ng/mL) | Part A: TEZ/IVA |
|---|---|
| VX-661 | 2070 ± 1390 |
| M1-661 | 4580 ± 2080 |
| IVA | 892 ± 700 |
| M1-IVA | 1740 ± 1070 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part B: TEZ/IVA |
|---|---|
| F/F Mutation | 1.7 ± 10.2 |
| F/RF Mutation | 8.3 ± 8.6 |
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).
| kg/m^2 | Part B: TEZ/IVA |
|---|---|
| F/F Mutation | 0.70 ± 1.45 |
| F/RF Mutation | 1.84 ± 2.21 |
The z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
| z-score | Part B: TEZ/IVA |
|---|---|
| F/F Mutation | -0.03 ± 0.71 |
| F/RF Mutation | 0.21 ± 0.46 |
Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.
| PEx events | Part B: TEZ/IVA |
|---|---|
| F/F Mutation | 386 |
| F/RF Mutation | 94 |
Collected over Day 1 Through Safety Follow-up Visit (up to Week 100 for Part A, up to Week 100 for Part B and up to Week 196 for Part C). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: TEZ/IVA | 1/1,042 (0.1%) | 351/1,042 (33.7%) | 938/1,042 (90%) |
| Part B: TEZ/IVA | 0/463 (0%) | 136/463 (29.4%) | 391/463 (84.4%) |
| Part C: TEZ/IVA | 0/204 (0%) | 44/204 (21.6%) | 149/204 (73%) |
| Event | Part A: TEZ/IVA | Part B: TEZ/IVA | Part C: TEZ/IVA |
|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 243/1042 | 103/463 | 28/204 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 25/1042 | 10/463 | 6/204 |
| Drug hypersensitivityImmune system disorders | 2/1042 | 2/463 | 3/204 |
| Distal intestinal obstruction syndromeGastrointestinal disorders | 12/1042 | 3/463 | 1/204 |
| PneumoniaInfections and infestations | 7/1042 | 4/463 | 1/204 |
| ConstipationGastrointestinal disorders | 8/1042 | 3/463 | 0/204 |
| Abdominal painGastrointestinal disorders | 7/1042 | 0/463 | 0/204 |
| InfluenzaInfections and infestations | 7/1042 | 1/463 | 0/204 |
| Blood creatine phosphokinase increasedInvestigations | 7/1042 | 0/463 | 0/204 |
| Intestinal obstructionGastrointestinal disorders | 4/1042 | 3/463 | 0/204 |
| Event | Part A: TEZ/IVA | Part B: TEZ/IVA | Part C: TEZ/IVA |
|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 444/1042 | 202/463 | 87/204 |
| CoughRespiratory, thoracic and mediastinal disorders | 374/1042 | 112/463 | 29/204 |
| NasopharyngitisInfections and infestations | 227/1042 | 88/463 | 13/204 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 223/1042 | 46/463 | 13/204 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 167/1042 | 64/463 | 25/204 |
| HeadacheNervous system disorders | 146/1042 | 47/463 | 20/204 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 136/1042 | 39/463 | 9/204 |
| PyrexiaGeneral disorders | 135/1042 | 40/463 | 20/204 |
| Upper respiratory tract infectionInfections and infestations | 135/1042 | 43/463 | 12/204 |
| DiarrhoeaGastrointestinal disorders | 105/1042 | 27/463 | 5/204 |
Baseline data is based on the parent study baseline, which is defined as the most recent non-missing measurements collected before the first dose of the study drug in the treatment period of parent studies. Baseline data is presented for all participants who signed informed consent and enrolled, or dosed, in Part A, Part B, or Part C, respectively in this study.
| Age, Continuous(years) | TEZ/IVA |
|---|---|
| Part A | 29.13 ± 12.00 |
| Part B | 29.61 ± 11.89 |
| Part C | 29.60 ± 11.68 |
| Sex: Female, Male(Participants) | TEZ/IVA |
|---|---|
| Part A — Female | 505 |
| Part A — Male | 539 |
| Part B — Female | 221 |
| Part B — Male | 243 |
| Part C — Female | 89 |
| Part C — Male | 115 |
| Race/Ethnicity, Customized(Participants) | TEZ/IVA |
|---|---|
| Part A — Hispanic or Latino | 25 |
| Part A — Not Hispanic or Latino | 1002 |
| Part A — Not collected per local regulations | 17 |
| Part B — Hispanic or Latino | 6 |
| Part B — Not Hispanic or Latino | 437 |
| Part B — Not collected per local regulations | 21 |
| Part C — Hispanic or Latino | 5 |
| Part C — Not Hispanic or Latino | 184 |
| Part C — Not collected per local regulations | 15 |
| Race/Ethnicity, Customized(Participants) | TEZ/IVA |
|---|---|
| Part A — White | 1017 |
| Part A — Black or African American | 7 |
| Part A — Asian | 2 |
| Part A — American Indian or Alaska Native | 1 |
| Part A — Native Hawaiian or Other Pacific Islander | 0 |
| Part A — Not collected per local regulations | 11 |
| Part A — Other | 6 |
| Part B — White | 447 |
| Part B — Black or African American | 1 |
| Part B — Asian | 2 |
| Part B — American Indian or Alaska Native | 0 |
| Part B — Native Hawaiian or Other Pacific Islander | 0 |
| Part B — Not collected per local regulations | 13 |
| Part B — Other | 1 |
| Part C — White | 193 |
| Part C — Black or African American | 0 |
| Part C — Asian | 1 |
| Part C — American Indian or Alaska Native | 0 |
| Part C — Native Hawaiian or Other Pacific Islander | 0 |
| Part C — Not collected per local regulations | 10 |
| Part C — Other | 0 |
Showing the first 100 of 159 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in May 2019, 45 months.
Results were first posted in Jun 2020, 1 year 1 month after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 45 months is above that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →